JP2019524100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524100A5 JP2019524100A5 JP2019502217A JP2019502217A JP2019524100A5 JP 2019524100 A5 JP2019524100 A5 JP 2019524100A5 JP 2019502217 A JP2019502217 A JP 2019502217A JP 2019502217 A JP2019502217 A JP 2019502217A JP 2019524100 A5 JP2019524100 A5 JP 2019524100A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immune cell
- car
- nucleic acid
- transposon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 102000008579 Transposases Human genes 0.000 claims 10
- 108010020764 Transposases Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 6
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 5
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 240000007019 Oxalis corniculata Species 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 241000282832 Camelidae Species 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363541P | 2016-07-18 | 2016-07-18 | |
| US62/363,541 | 2016-07-18 | ||
| US201662410581P | 2016-10-20 | 2016-10-20 | |
| US62/410,581 | 2016-10-20 | ||
| PCT/CA2017/050860 WO2018014122A1 (en) | 2016-07-18 | 2017-07-17 | Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524100A JP2019524100A (ja) | 2019-09-05 |
| JP2019524100A5 true JP2019524100A5 (enExample) | 2020-08-27 |
| JP7178568B2 JP7178568B2 (ja) | 2022-11-28 |
Family
ID=60941975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502217A Active JP7178568B2 (ja) | 2016-07-18 | 2017-07-17 | がんを治療するための癌胎児性抗原関連細胞接着分子６を標的とするｃａｒ免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11242386B2 (enExample) |
| EP (1) | EP3485017A4 (enExample) |
| JP (1) | JP7178568B2 (enExample) |
| KR (1) | KR20190057275A (enExample) |
| CN (1) | CN109477114A (enExample) |
| AU (1) | AU2017299854A1 (enExample) |
| CA (1) | CA3031289A1 (enExample) |
| IL (1) | IL264223A (enExample) |
| PL (1) | PL240585B1 (enExample) |
| WO (1) | WO2018014122A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617720B2 (en) * | 2016-10-20 | 2020-04-14 | Miltenyi Biotech, GmbH | Chimeric antigen receptor specific for tumor cells |
| AU2019401282A1 (en) * | 2018-12-20 | 2021-07-15 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| CN111041064A (zh) * | 2019-07-22 | 2020-04-21 | 徐州医科大学 | 一种体外评价car-t杀伤活性的方法 |
| JP7769325B2 (ja) | 2019-07-23 | 2025-11-13 | 株式会社東芝 | Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット |
| US20230357427A1 (en) * | 2020-08-19 | 2023-11-09 | Shanghai Immunohead Biotechnology Co., Ltd | Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use |
| CA3205463A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
| EP4320435A1 (en) * | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| WO2024084852A1 (ja) * | 2022-10-20 | 2024-04-25 | 国立大学法人三重大学 | Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、並びにｃａｒを含む免疫細胞の製造方法 |
| WO2025006562A1 (en) * | 2023-06-27 | 2025-01-02 | Bio4T2, Llc | Methods of car administration and treatment |
| WO2025029484A1 (en) * | 2023-07-31 | 2025-02-06 | Bio4T2, Llc | Methods of blood cell-mediated in vivo car cell expansion and engraftment |
| CN120041501A (zh) * | 2023-11-10 | 2025-05-27 | 上海细胞治疗集团药物技术有限公司 | 一种表达嵌合抗原受体的细胞的制备方法 |
| CN120463811A (zh) * | 2025-07-16 | 2025-08-12 | 上海健康医学院 | 一种靶向ceacam6的纳米抗体及其制备方法与用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001062895A2 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
| WO2009003671A2 (en) | 2007-07-04 | 2009-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| WO2012040824A1 (en) | 2010-10-01 | 2012-04-05 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| MX374681B (es) | 2013-05-13 | 2025-03-06 | Cellectis | Receptor quimérico de antígeno específico para cd19 y sus usos. |
| CN105408473B9 (zh) * | 2013-05-14 | 2021-09-17 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
| US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| PL3083671T3 (pl) * | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
| US11041021B2 (en) * | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| EP3215139B1 (en) | 2014-11-03 | 2020-08-19 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
-
2017
- 2017-07-17 CA CA3031289A patent/CA3031289A1/en not_active Abandoned
- 2017-07-17 AU AU2017299854A patent/AU2017299854A1/en not_active Abandoned
- 2017-07-17 WO PCT/CA2017/050860 patent/WO2018014122A1/en not_active Ceased
- 2017-07-17 PL PL422231A patent/PL240585B1/pl unknown
- 2017-07-17 US US15/651,692 patent/US11242386B2/en active Active
- 2017-07-17 JP JP2019502217A patent/JP7178568B2/ja active Active
- 2017-07-17 CN CN201780044780.1A patent/CN109477114A/zh active Pending
- 2017-07-17 EP EP17830145.3A patent/EP3485017A4/en not_active Withdrawn
- 2017-07-17 KR KR1020197001589A patent/KR20190057275A/ko not_active Ceased
-
2019
- 2019-01-13 IL IL264223A patent/IL264223A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524100A5 (enExample) | ||
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| JP7390345B2 (ja) | アゴニスト性ｔｎｆ受容体結合物質 | |
| KR102713223B1 (ko) | 항-pd-l1 항체 | |
| TWI548418B (zh) | Anti-NR10 / IL-31RA antibody and its use | |
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| CN110799540B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2024091842A (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP2019511212A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| CN111393529B (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| CN106986939B (zh) | 抗pd-1和tem-8双特异性抗体及其应用 | |
| JP2016514457A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| AU2021238341A1 (en) | Miniature guidance and navigation control (miniGNC) antibody-like proteins and methods of making and using thereof | |
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| US20210395380A1 (en) | Variant antibodies that bind ox40 | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CN113164777A (zh) | Csf1r/ccr2多特异性抗体 | |
| JP2023536631A (ja) | 多重特異性結合性作用剤およびその使用 | |
| IL303535A (en) | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics |